准微质激活以调节阿尔茨海默氏病中神经炎症的发生
Vinay Patil1, Amit Sharma1, Bhavin Parekh1
1Arnold and Marie Schwartz College of Pharmacy, Long Island University, Brooklyn, NY, 11201, USA.
Neuromolecular medicine
|December 4, 2025
概括
微质细胞,大脑的免疫细胞,在阿尔茨海默病中从保护性转变为破坏性作用. 准微质激活通路为神经炎症提供了潜在的治疗策略.
科学领域:
- 神经科学是一个神经科学.
- 免疫学 免疫学 免疫学
- 病理学 病理学 病理学
背景情况:
- 阿尔茨海默病 (AD) 涉及粉样斑块和神经纤维状,导致认知能力下降.
- 由微质激活驱动的神经炎症是AD病理学的核心.
- 微细胞表型是动态的,影响神经保护或神经退行.
研究的目的:
- 在阿尔茨海默病中审查微质表型转变.
- 总结调节微质激活的信号机制.
- 探索调节AD中神经炎症的治疗潜力.
主要方法:
- 关于微质细胞和阿尔茨海默病的当前科学文献的综述.
- 参与微质激活的分子通路 (JAK-STAT,PI3K-AKT,MAPK) 的分析.
- 检查治疗点,如TREM2和P2X7受体.
主要成果:
- 微质最初表现出抗炎作用,有助于清除斑块.
- 慢性或失调的微质激活促进了亲炎症状态,增加了神经元损伤.
- 关键的信号通路调节这些表型变化.
结论:
- 调节微质激活为AD提供了一个有前途的治疗途径.
- 策略包括增强神经保护,抑制炎症和向特定受体.
- 进一步了解质相互作用和激活驱动因素对于新型AD治疗至关重要.
更多相关视频
09:12Isolation of Cortical Microglia with Preserved Immunophenotype and Functionality From Murine Neonates
Published on: January 30, 2014
16.6K
09:33Quantitative 3D In Silico Modeling q3DISM of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease
Published on: December 26, 2016
8.3K
相关概念视频
01:22Alzheimer's Disease: Treatment
736
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
736
01:26Alzheimer's Disease: Overview
1.5K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.5K